
Opinion|Podcasts|November 22, 2024
Challenges With Current Treatment Options for CSU
Key Takeaways
- Biologics for CSU face challenges including high costs, side effects, and the necessity for accurate patient selection to ensure treatment efficacy.
- BTK is a key player in mast cell degranulation, making it an ideal target for CSU treatment by potentially reducing histamine release.
Panelists discuss the challenges associated with using biologics for chronic spontaneous urticaria (CSU), including issues related to accessibility and cost, while also explaining why Burton tyrosine kinase (BTK) is considered an ideal target for CSU treatment due to its role in mediating mast cell degranulation.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What are the challenges associated with the use of biologics for CSU?
- We previously discussed the role that BTK plays in mediating mast cell degranulation. Why does this make BTK an ideal target for CSU treatment?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
Rethinking “Type 2”: Inside the 2026 AACE Diabetes Classification Algorithm
2
VIASKIN Peanut Patch Efficacy Holds in Kids With Atopic Comorbidities
3
Fezolinetant Shows No CNS Safety Signal in Pooled Analysis of 3100 Women, With Marla Shapiro, CM
4
CAPTAIN-T2D: Interim Results Display High Cortisol Prevalence in Difficult-to-Control T2D
5
























































